< back to search

Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial.

Bao, Chunde   •   Huang, Feng   •   Khan, Muhammad Asim   •   Fei, Kaiyin   •   Wu, Zhong   •   Han, Chenglong   •   Hsia, Elizabeth C

published in: Rheumatology (Oxford, England)



endpoint

Golimumab has (optional: compared with placebo) proved to be better.
general condition better


basics

diagnosis:
ankylosing spondylitis
ankylosing spondylitis

localization:
not specified

method:
conservative therapy → injection
conservative therapy → injection therapy
conservative therapy → injection therapy
conservative therapy → injection

publication details

10.1093/rheumatology/keu132
pubmed
24729398
2014
randomized controlled trial
yes
prospective
1+

▼
▲